EcoDrugPlus

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005004354
Gene Symbol: RET
1 Cross references
199 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-B-Like

Ensembl ID : ENSOTSG00005016449
Gene Symbol: LOC112247455
2 Cross references
174 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-B-Like

Ensembl ID : ENSOTSG00005011129
Gene Symbol: LOC112247455
2 Cross references
174 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSOTSG00005042617
Gene Symbol: LOC112234836
2 Cross references
389 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSOTSG00005011073
Gene Symbol: LOC112229923
2 Cross references
374 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSOTSG00005041136
Gene Symbol: RARG
1 Cross references
324 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSOTSG00005029782
Gene Symbol: RARG
3 Cross references
369 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSOTSG00005003820
Gene Symbol: RARG
1 Cross references
369 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSOTSG00005019640
Gene Symbol: RARG
1 Cross references
324 Possible Orthologues:

Rho-Associated Protein Kinase 1-Like

Ensembl ID : ENSOTSG00005043917
Gene Symbol: LOC112226775
3 Cross references
207 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSOTSG00005043979
Gene Symbol: LOC112232894
3 Cross references
218 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSOTSG00005030695
Gene Symbol: LOC112232894
3 Cross references
218 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).